Clinical data | |
---|---|
Routes of administration | Injection [1] [2] |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | <3% ( oral) [1] |
Elimination half-life | 44 minutes ( IV) [1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C45H60N10O14 |
Molar mass | 965.031 g·mol−1 |
3D model ( JSmol) | |
| |
|
Nepadutant ( INN) (code name MEN-11420) is a glycosylated bicyclic cyclo hexapeptide drug which acts as a highly selective NK2 receptor antagonist. [2] [3] [4] It was developed by the Menarini Group and investigated for the treatment of functional gastrointestinal disorders and asthma but was never marketed. [3] [5] [6]